7,100 Shares in LivaNova PLC (NASDAQ:LIVN) Acquired by Bayesian Capital Management LP

Bayesian Capital Management LP bought a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 7,100 shares of the company’s stock, valued at approximately $397,000.

Several other hedge funds and other institutional investors have also modified their holdings of LIVN. Norges Bank bought a new position in shares of LivaNova during the 4th quarter worth approximately $26,064,000. Mesirow Institutional Investment Management Inc. acquired a new stake in LivaNova during the 1st quarter valued at $13,816,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in LivaNova during the 4th quarter valued at $8,330,000. Magnetar Financial LLC increased its holdings in LivaNova by 24.5% during the 1st quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock valued at $42,142,000 after purchasing an additional 148,178 shares in the last quarter. Finally, abrdn plc acquired a new stake in LivaNova during the 4th quarter valued at $5,613,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Up 1.6 %

Shares of LivaNova stock traded up $0.82 on Wednesday, hitting $52.12. The stock had a trading volume of 93,504 shares, compared to its average volume of 651,627. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47. The business’s 50 day moving average is $54.71 and its two-hundred day moving average is $54.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.45 by $0.28. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The company had revenue of $294.90 million for the quarter, compared to the consensus estimate of $278.17 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities research analysts predict that LivaNova PLC will post 2.6 earnings per share for the current year.

Insider Activity at LivaNova

In related news, Director Daniel Jeffrey Moore sold 56,623 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the sale, the director now directly owns 27,534 shares in the company, valued at $1,655,068.74. The sale was disclosed in a filing with the SEC, which is available at this link. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LIVN shares. Robert W. Baird raised their price target on LivaNova from $58.00 to $66.00 and gave the company a “neutral” rating in a report on Thursday, May 2nd. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Stifel Nicolaus lifted their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Needham & Company LLC restated a “buy” rating and issued a $72.00 price target on shares of LivaNova in a report on Thursday, June 6th. Finally, Mizuho boosted their price target on LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and an average price target of $67.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.